Evidence map›Paper›PMID 29370236›Full record

ArticlePloS one2018

Ethyl pyruvate inhibits oxidation of LDL in vitro and attenuates oxLDL toxicity in EA.hy926 cells.

Christine Rossmann, Christoph Nusshold, Margret Paar, Gerhard Ledinski, Erwin Tafeit, Martin Koestenberger, Eva Maria Bernhart, Wolfgang Sattler, Gerhard Cvirn, Seth Hallström

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Tackling Atherosclerosis via Selected Nutrition.International journal of molecular sciences · 2022
    Review
  5. Ethyl pyruvate, a versatile protector in inflammation and autoimmunity.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2022
    Review
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Christine RossmannInstitute of Physiological Chemistry, Medical University of Graz, Graz, Austria.
Christoph NussholdInstitute of Physiological Chemistry, Medical University of Graz, Graz, Austria.
Margret PaarInstitute of Physiological Chemistry, Medical University of Graz, Graz, Austria.
Gerhard LedinskiInstitute of Physiological Chemistry, Medical University of Graz, Graz, Austria.
Erwin TafeitInstitute of Physiological Chemistry, Medical University of Graz, Graz, Austria.
Martin KoestenbergerDepartment of Pediatrics, Medical University of Graz, Graz, Austria.
Eva Maria BernhartInstitute of Molecular Biology and Biochemistry, Medical University of Graz, Graz, Austria.
Wolfgang SattlerInstitute of Molecular Biology and Biochemistry, Medical University of Graz, Graz, Austria.
Gerhard CvirnInstitute of Physiological Chemistry, Medical University of Graz, Graz, Austria.ORCID 0000-0002-1410-1844
Seth HallströmInstitute of Physiological Chemistry, Medical University of Graz, Graz, Austria.
Medical University of Graz · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEthyl pyruvate (EP) exerts anti-inflammatory and anti-oxidative properties. The aim of our study was to investigate whether EP is capable of inhibiting the oxidation of LDL, a crucial step in atherogenesis. Additionally, we examined whether EP attenuates the cytotoxic effects of highly oxidized LDL in the human vascular endothelial cell line EA.hy926.

methodsNative LDL (nLDL) was oxidized using Cu2+ ions in the presence of increasing amounts of EP. The degree of LDL oxidation was quantified by measuring lipid hydroperoxide (LPO) and malondialdehyde (MDA) concentrations, relative electrophoretic mobilities (REMs), and oxidation-specific immune epitopes. The cytotoxicity of these oxLDLs on EA.hy926 cells was assessed by measuring cell viability and superoxide levels. Furthermore, the cytotoxicity of highly oxidized LDL on EA.hy926 cells under increasing concentrations of EP in the media was assessed including measurements of high energy phosphates (ATP).

resultsOxidation of nLDL using Cu2+ ions was remarkably inhibited by EP in a concentration-dependent manner, reflected by decreased levels of LPO, MDA, REM, oxidation-specific epitopes, and diminished cytotoxicity of the obtained oxLDLs in EA.hy926 cells. Furthermore, the cytotoxicity of highly oxidized LDL on EA.hy926 cells was remarkably attenuated by EP added to the media in a concentration-dependent manner reflected by a decrease in superoxide and an increase in viability and ATP levels.

conclusionsEP has the potential for an anti-atherosclerotic drug by attenuating both, the oxidation of LDL and the cytotoxic effect of (already formed) oxLDL in EA.hy926 cells. Chronic administration of EP might be beneficial to impede the development of atherosclerotic lesions.

Indexed as

Anti-Inflammatory AgentsAntioxidantsApoptosisCell LineCell SurvivalCholesterol, LDLEndothelial CellsEndotheliumHumansLipoproteins, LDLMalondialdehydeOxidation-ReductionOxidative StressPyruvatesAnti-Inflammatory AgentsAntioxidantsCholesterol, LDLethyl pyruvateLipoproteins, LDLMalondialdehydeoxidized low density lipoproteinPyruvates

Identifiers

PMID29370236
PMCPMC5784938
OpenAlexW2784613100

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.